Skip to main content

Accelrys Cuts Loss 84 Percent on Slight Quarterly Revenue Gain

NEW YORK (GenomeWeb News) - Accelrys yesterday reported a 2 percent increase in fiscal fourth-quarter revenues as R&D spending fell 22 percent and the company cut its quarterly loss by 84 percent.
 
Total receipts for the three months ended March 31, 2007, increased to $19.9 million from $19.4 million year over year.
 
Accelrys said growth in its SciTegic Pipeline Pilot product line was offset by reduced sales of legacy products that were “deemphasized" due to product line restructuring.
 
R&D spending decreased to $4.2 million from $5.3 million year over year.
 
Net loss dropped to $1.1 million from $6.4 million in the year-ago period. Accelrys said cost controls it implemented over the past two years helped it reduce its loss for the quarter.
 
Accelrys said it had around $70.8 million in cash, cash equivalents and marketable securities as of March 31.

Filed under

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.